Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
2022 · BMC Cancer · 20 citations
https://doi.org/10.1186/s12885-022-09364-z
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
60
Papers
280
Citations
11
h-index
11
i10-index
Sreevalsa Appukkuttan is an academic researcher from Bayer (United States). The author has contributed to research in topics: Prostate Cancer Treatment and Research & Radiopharmaceutical Chemistry and Applications & Lymphoma Diagnosis and Treatment. The author has an h-index of 11, co-authored 51 publications.
ORCID: 0000-0003-2537-1687https://doi.org/10.1186/s12885-022-09364-z
https://doi.org/10.1001/jamanetworkopen.2023.37272
Click to start Chat